Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

providers and patients to better manage PKU. These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Human studies are planned for 2010. Regulatory approval and commercial availability of the handheld blood Phe monitor is expected in the first half of 2011.
  • BMN-185 - IgA protease for IgA nephropathy: BioMarin is completing early preclinical work and expects to move to the next phase of research in the first half of 2010. IgA proteases have been shown to cleave IgA complexes, the deposition of which causes IgA nephropathy, an orphan kidney disorder with few treatment alternatives.
  • Additional early development candidates: BioMarin is working on multiple early development opportunities and expects to announce the next IND candidate in the first half of 2010.
  • BMN-103 - a-glucosidase (GAA) for Pompe Disease: BMN-103 is a highly phosphorylated GAA enzyme, which the company believes could result in more efficient uptake in cells and potentially lead to improved glycogen reduction in key affected muscle groups not addressed with current therapy. BioMarin continues to explore partnering options for this program.
  • 6R-BH4 Cardiovascular: BioMarin has decided to put the PAH opportunity for 6R-BH4 on hold, pending discussions with potential partners. Although the early data suggest a potential for 6R-BH4 to be a safe and efficacious therapy for PAH, BioMarin decided that the additional investment in time and resources required to demonstrate this effect is better allocated to other early pipeline candidates.
  • Non-GAAP Financial Information and Reconciliation

    The above results for the quarter and nine months ended September 30, 2009 and 2008, full year results for 2008 and financial guidance for 2009 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is cal
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. BioMarin to Present at the Oppenheimer Healthcare Conference
    2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    7. BioMarin Announces FDA Approval for Kuvan
    8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    9. Rigel Announces Presentations at Two Investor Conferences
    10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
    11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research ... announced the addition of the "Medical Device ... to their offering. This report analyzes ... US$ Million by the following Device Categories: Class ... areas also analyzed in the report Include - ...
    (Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
    (Date:4/17/2015)... 2015 Steven Rash , the CEO of ... operating subsidiary American Seed & Oil Company, presented the ... yesterday in New York City.  Mr. Rash,s presentation featured ... Seed & Oil Company has recently announced the ... Seed Foods , the EpiVape , and ...
    Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
    ... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... patent 7,893,245, titled "Interfering RNA Molecules," by the ... issued patent, which represents a continuation of previously ... RNAi molecules with defined positional modifications including siRNA ...
    ... Feb. 22, 2011 Covance Inc. (NYSE: CVD ... Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
    Cached Medicine Technology:Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 2Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 3Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials 4Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference 2
    (Date:4/17/2015)... 17, 2015 Wholelifelifeinsurance.org has released ... whole life insurance policies . , Whole ... financial security for their families at the same time. ... options which can be customized to it the client’s ... reduced if clients take some appropriate steps.Comparing life insurance ...
    (Date:4/17/2015)... Verndale, a Global Experience Technology Company, is pleased ... as a Boston Business Journal (BBJ) Pacesetter, ranking as ... The BBJ’s Pacesetters represents privately held businesses that recorded ... is the eighth consecutive year and the ninth time ... honored with this award. , “Being honored with this ...
    (Date:4/17/2015)... 17, 2015 Cheapquotesautoinsurance.com has released a new ... has a salvage title . , An auto insurance ... a salvage title if the owner has paid for all ... title car is not possible, while in other states, the ... blog post provides more information on the subject. , ...
    (Date:4/17/2015)... 17, 2015 Founder of the ... as a keynote speaker at the Couples Conference from ... Marriott in Manhattan Beach, CA. Tatkin’s presentation and panel ... can help couples become “secure-functioning” – a term he ... of research in neurobiology, arousal regulation, and infant attachment ...
    (Date:4/17/2015)... (PRWEB) April 17, 2015 The American ... that Long Island eye surgeon Jeffrey L. Martin, will ... Cataract Surgery Skills Transfer Session being held April 17-21 ... Martin is the Managing Partner of North Shore Eye ... fellow ophthalmologists attending the Skills Transfer Session in learning ...
    Breaking Medicine News(10 mins):Health News:Whole Life Insurance Policies At Affordable Prices By Comparing Quotes 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 2Health News:Best-Selling Author, Therapist and Founder of the PACT Institute Will Give a Keynote Address at 2015 Couples Conference 3Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 2Health News:American Society of Cataract & Refractive Surgery Selects Dr. Jeffrey Martin To Serve As Lead Instructor For Laser Cataract Surgery Skills Transfer Session 3
    ... important regulatory enzyme may slow the loss of brain ... disorders. In a report receiving advance online publication ... (MGH)-based research team reports that increased expression of Sirt1, ... the brain of a mouse model of HD protected ...
    ... a dentist but not a general healthcare provider, according to an ... Health . The study, conducted by a nursing-dental research team ... proportion of Americans who are seen annually by a dentist but ... suggests dentists can play a crucial role as health care practitioners ...
    ... Reporter , FRIDAY, Dec. 16 (HealthDay News) -- Not only does ... in their quality of life, new research finds. ... are a lot of benefits that you might not have thought ... you,d have more stress, that quitting would put more stress on ...
    ... for the treatment of breast cancer has been ... the U.S. as an alternative to standard whole-breast ... 16th in the Journal of the ... APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy ...
    ... , FRIDAY, Dec. 16 (HealthDay News) -- First responders ... than double the rate of the general U.S. population, new ... 8 in the American Journal of Industrial Medicine , ... the result of their exposure to the toxic dust created ...
    ... Road Rippers Lightning Rods, Let,s Rock Elmo and the I ... season, parents should ensure that their children don,t risk permanent ... Department of Otolaryngology measured the noise levels of two dozen ... precise gauging in a soundproof booth at UC Irvine Medical ...
    Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:NYU study concludes that dentists could screen 20 million Americans for chronic physical illnesses 2Health News:Life After Cigarettes Is Happier: Study 2Health News:Life After Cigarettes Is Happier: Study 3Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:WTC First Responders More Likely to Have Asthma: Study 2Health News:UC Irvine researchers urge caution when buying noisy toys 2
    Total IgE Control...
    The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
    ... The K-ASSAY ASO / ... is intended to be used ... of known concentration for monitoring ... O (ASO), Rheumatoid Factor (RF), ...
    Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
    Medicine Products: